ATF (adenosine-5′-triphosphatogistidino-magnesium) solution for injections ampoules 1% 1ml. №10

active ingredient: adenosine;

1 ml of solution contains ATP disodium salt (adenosine triphosphate disodium salt) 10 mg;

excipients: sodium hydroxide, water for injection.

Injection.

Basic physical and chemical properties: transparent colorless or slightly yellowish liquid.

Other cardiac drugs. Adenosine ATX code C01E B10.

Adenosine triphosphate (ATP) is a natural macroergic compound. It is synthesized in almost all tissues of the body by oxidative phosphorylation and in the process of carbohydrate breakdown. Most of all, it is synthesized in muscle tissue, where the energy contained in ATP molecules is used during muscle contraction. The energy released during the breakdown of ATP is used in the synthesis of, in particular, protein, urea.

In the nervous system, ATP molecules act as a neurotransmitter, transmitting a signal in purinergic synapses. At the same time, ATP accompanies acetylcholine and noradrenergic mediation.

When administered systemically, sodium adenosine triphosphate-Darnitsa has a metabolic, membrane-stabilizing, antiarrhythmic effect, improves cerebral and coronary circulation. The antiarrhythmic effect is associated with the suppression of the automatism of the sinus node and the conduction of impulses along the Purkinje fibers. Promotes relaxation of smooth muscles. Improves antioxidant protection of the myocardium, increases its contractility.

Partially blocks calcium channels and facilitates the transmembrane movement of potassium ions.

As part of the complex therapy of muscular dystrophy and atrophy; for the relief of paroxysms of supraventricular tachycardia; with spasms of peripheral vessels (intermittent claudication, Raynaud’s disease, thromboangiitis obliterans).

Treatment of central, peripheral and mixed forms of hereditary pigmentary retinal degeneration.

Individual hypersensitivity to any of the components of the drug, acute myocardial infarction, arterial hypotension, severe forms of bradyarrhythmias, II-III degree AV blockade, decompensated stage of heart failure, cardiogenic shock and other types of shocks, QT prolongation syndrome, hemorrhagic stroke; hyperkalemia, hypermagnesemia; inflammatory diseases of the lungs, chronic obstructive pulmonary diseases (eg bronchial asthma); period of pregnancy or lactation, children’s age. You can not enter simultaneously with cardiac glycosides in large doses.